Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982393 · ClinicalTrials.gov registry record
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
A clinical trial of Primary Hyperoxaluria Type 1, sponsored by Alnylam Pharmaceuticals.
- Active
- Registry status
- 207
- Enrollment target
- 20
- Study locations
NCT04982393 is a study of Primary Hyperoxaluria Type 1 that is active but no longer recruiting, run by Alnylam Pharmaceuticals. The registered enrollment target is 207 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT04982393, a study of Primary Hyperoxaluria Type 1, is active but no longer recruiting, sponsored by Alnylam Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Ghent
- Clinical Trial Site - Liège
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Lyon
- Clinical Trial Site - Paris
- Clinical Trial Site - Berlin
- Clinical Trial Site - Cologne
- Clinical Trial Site - Hamburg
- Clinical Trial Site - Jerusalem
Texas
- Clinical Trial Site - Dallas
- Clinical Trial Site - Houston
Ontario
- Clinical Trial Site - Hamilton
- Clinical Trial Site - Toronto
Arizona
- Clinical Trial Site - Phoenix
District of Columbia
- Clinical Trial Site - Washington D.C.
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Rochester
Ohio
- Clinical Trial Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2028-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04982393
The ClinicalTrials.gov registry entry for NCT04982393 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Hyperoxaluria Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT04982393 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT04982393 about?
NCT04982393 is a clinical study titled "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)". The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
What is the current status of trial NCT04982393?
This trial is currently active not recruiting. The enrollment target is 207 participants. The study started on 2021-12-13. Estimated completion is 2028-09-01.
What conditions does trial NCT04982393 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria Type 1.
Who is sponsoring clinical trial NCT04982393?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04982393 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperoxaluria Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.